{"data":{"id":"us-dc/d.c.-code-7-1671.05-perm","jurisdiction":"us-dc","citation":"D.C. Code § 7-1671.05(Perm)","heading":"Medical cannabis program.","body":"\n      *NOTE: This codification is not the most current, due to recent law changes. To see the current law (including emergency and temporary legislation, if relevant) click this link: Current Version*\n      \n\n(a)\nThere is established a medical cannabis program, which shall regulate the cultivation, manufacture, distribution, dispensing, purchase, delivery, sale, possession, administration, and testing of medical cannabis and the manufacture, distribution, purchase, sale, possession, and use of paraphernalia.\n\n(b)\nThe Program shall:\n(1)\nRequire the registration with ABCA of all:\n(A)\nQualifying patients, except qualifying patients enrolled in another jurisdiction's medical cannabis program pursuant to § 7-1671.02(c)(2), and the caregivers of qualifying patients; and\n(B)\nNon-resident cardholders;\n(2)\nRequire the licensing with ABCA of all cultivation centers, manufacturers, retailers, internet retailers, couriers, and testing laboratories, including all directors, officers, members, incorporators, agents, and employees of those facilities;\n(3)\n\"_______________________________________________\n(4)\n(A)\nAs part of the registration process, permit a non-resident qualifying patient visiting the District of Columbia to apply to ABCA to receive a temporary non-resident registration identification card, which shall be valid for 30 days; and\n(B)\nAfter the expiration of a temporary non-resident registration identification card, permit a non-resident qualifying patient to apply to ABCA to be issued another 30-day temporary non-resident identification card.\n(5)\nIssue nontransferable registration identification cards to persons and entities registered pursuant to paragraph (1) of this subsection; provided, that:\n(A)\nWith respect to registration identification cards issued to persons and entities registered pursuant to paragraph (1)(A) and (C) of this subsection, such cards expire every 2 years:\n(B)\nThe cards may be presented to and used by law enforcement to confirm whether a person or entity is authorized to cultivate, manufacture, distribute, dispense, deliver, sell, possess, test, or administer medical cannabis or medical cannabis products, or manufacture, possess, deliver, purchase, sell,  distribute, or use paraphernalia; and\n(C)\nThe ABC Board may, by rule, establish license and registration periods and fees under the section that are valid for one year, 2 years, or 3 years.\n(6)\nRequire all cultivation centers, manufacturers, retailers, internet retailers, couriers, and testing laboratories to:\n(A)\nMaintain true, complete, and real-time electronic records of:\n(i)\nThe name, address, home telephone number, and date of birth of each employee;\n(ii)\nEach transaction conducted by the facility, including:\n(I)\nThe quantity of medical cannabis tested, processed, distributed, delivered, or dispensed;\n(II)\nThe consideration given for the medical cannabis, if any; and\n(III)\nThe recipient of the medical cannabis;\n(iii)\nThe quantity of medical cannabis or medical cannabis products at the cultivation center, manufacturer, retailer, internet retailer, or testing laboratory;\n(iv)\nThe disposal method used for any medical cannabis that was cultivated, processed, or acquired but did not meet the requirements for sale established by the ABC Board through rulemaking pursuant to § 7-1671.13 or that was not sold for any other reason, including evidence of the disposal of the medical cannabis; and\n(v)\nAny other information required by ABCA; and\n(B)\nNotify ABCA and the Chief of the Metropolitan Police Department in writing and within 24 hours of the loss, theft, or destruction of any medical cannabis;\n(7)\nRequire all retailers and internet retailers to maintain true, complete, and real-time electronic records of the name and address of the qualifying patient or caregiver authorized to obtain medical cannabis;\n(8)\nUpon the licensing of at least one testing laboratory pursuant to paragraph (2) of this subsection, require that cultivation centers segregate all harvested medical cannabis into batches before manufacturing any medical cannabis products, or packaging dried medical cannabis for sale to a manufacturer, retailer, or internet retailer, and hold the harvested medical cannabis from sale until:\n(A)\nThe medical cannabis has been tested by a testing laboratory;\n(B)\nThe cultivation center has received the information required pursuant to paragraph (9) of this subsection; and\n(C)\nThe cultivation center has determined that the medical cannabis meets the requirements for sale established by the ABC Board through rulemaking;\n(9)\nRequire testing laboratories to provide cultivation centers with the following information after testing harvested medical cannabis samples:\n(A)\nThe concentration of tetrahydrocannabinol and cannabidiol in the testing material;\n(B)\nWhether the tested material is organic or inorganic;\n(C)\nThe presence and concentration of fertilizers or other nutrients;\n(D)\nThe presence of mold, mildew, or pests;\n(E)\nWhether the medical cannabis samples contain mycotoxin, pesticides, or heavy metals above a threshold determined by the ABC Board through rulemaking; and\n(F)\nAny other information that the ABC Board may require through rulemaking;\n(10)\nUpon licensing of at least one testing laboratory pursuant to paragraph (2) of this section, require that manufacturers segregate all processed medical cannabis products into batches, and hold the processed medical cannabis products from sale until:\n(A)\nThe medical cannabis products have been tested by a testing laboratory;\n(B)\nThe manufacturer has received the information required pursuant to paragraph (11) of this subsection; and\n(C)\nThe manufacturer has determined that the medical cannabis products meet the requirements for sale established by the ABC Board through rulemaking;\n(11)\nRequire testing laboratories to provide manufacturers with the following information after testing medical cannabis product samples:\n(A)\nThe concentration of tetrahydrocannabinol and cannabidiol in the testing material;\n(B)\nWhether the tested material is organic or inorganic;\n(C)\nThe presence and concentration of fertilizers or other nutrients;\n(D)\nWhether the medical cannabis product samples contain mycotoxin or residual solvents above a threshold determined by the ABC Board through rulemaking; and\n(E)\nAny other information that the ABC Board may require through rulemaking;\n(12)\nDevelop educational materials about:\n(A)\nThe potential adverse drug interactions that could occur from using medical cannabis concurrently with other medical treatments;\n(B)\nHarm reduction strategies for qualifying patients who use medical cannabis; and\n(C)\nThe importance of informing health care providers and pharmacists of the use of medical cannabis to help avoid adverse drug interactions;\n(13)\nRevoke or suspend the registration or license of any person or entity if the ABC Board determines that the person or entity has violated a provision of Chapter 16B of Title 7 or the rules issued pursuant to § 7-1671.13;\n(14)\nConduct announced and unannounced inspections of cultivation centers, manufacturers, retailers, internet retailers, couriers, and testing laboratories;\n(15)\nEstablish sliding-scale registration and annual renewal fees for all persons and entities required to register or obtain a license pursuant to Chapter 16B of Title 7; provided, that the licensing and annual renewal fees for cultivation centers, manufacturers, retailers, internet retailers, couriers, and testing laboratories and for the directors, officers, members, incorporators, agents, and employees of cultivation centers, manufacturers, retailers, internet retailers, couriers, and testing laboratories be sufficient to offset the cost of administering Chapter 16B of Title 7;\n(16)\nEstablish a system to provide for the safe and affordable dispensing of medical cannabis to qualifying patients who are unable to afford a sufficient supply of medical cannabis based upon the qualifying patient's income and existing financial resources that:\n(A)\nAllows qualifying patients to apply to the ABC Board to be eligible to purchase medical cannabis from retailers and internet retailers at prices set on a sliding scale based upon the qualifying patient's income and existing financial resources; and\n(B)\nRequires each retailer and internet retailer to provide medical cannabis at prices set on the sliding scale described in subparagraph (A) of this paragraph, as determined by the ABC Board, to qualifying patients determined eligible pursuant to subparagraph (A) of this paragraph;\n(17)\nEstablish standards by which applicants for cultivation center, manufacturer, retailer, internet retailer, courier, or testing laboratory license are evaluated for licensing or license renewal, which may include:\n(A)\nAn applicant's knowledge of District and federal law relating to cannabis and rules issued pursuant to § 7-1671.13;\n(B)\nA security plan that has been assessed by the Metropolitan Police Department; and\n(C)\nA cultivation plan;\n(18)\n(A)\nProvide electronic notice to the Councilmember and all Advisory Neighborhood Commissions in the affected ward at least 45 calendar days prior to the approval of a location for a cultivation center, manufacturer, retailer, or internet retailer; and\n(B)\nAccord great weight to input provided by the Advisory Neighborhood Commission regarding the proposed location of a cultivation center, manufacturer, retailer, or internet retailer when approving or rejecting an application for a license;\n(C)\nEstablish procedures by which Advisory Neighborhood Commissions can protest new and renewal applications for a cultivation center, manufacturer, retailer, or internet retailer when approving or rejecting an application for a license; and\n(D)\nEstablish procedures for an Advisory Neighborhood Commission to enter into a settlement agreement for a cultivation center, manufacturer, retailer, or internet retailer.\n(19)\nRequire caregivers and qualifying patients to notify ABCA within 48 hours and in writing of the loss, theft, or destruction of a registration identification card; and\n(20)\nSubmit to the Council an annual report that includes:\n(A)\nThe number of qualifying patients participating in the medical cannabis program;\n(B)\nThe number of qualifying patients and caregivers registered;\n(C)\nThe number of registration identification cards suspended and revoked;\n(D)\nThe number of authorized practitioners providing written recommendations for qualifying patients;\n(E)\nThe number and location of cultivation centers, manufacturers, retailers, internet retailers, and testing laboratories;\n(F)\nThe amount of cannabis harvested by cultivation centers;\n(G)\nThe dollar amount of medical cannabis or medical cannabis products sold by cultivation centers, manufacturers, retailers, and internet retailers; and\n(H)\nThe number and types of violations of Chapter 16B of Title 7 and any applicable rules, taken against licensed cultivation centers, manufacturers, retailers, internet retailers, couriers, and testing laboratories.","path":["Title 99. Reserved sections."],"source_url":"https://code.dccouncil.gov/us/dc/council/code/sections/7-1671.05(Perm)","current_through":"2026-08-20 (D.C. Law 26-175)","vintage":"","retrieved_at":"2026-08-29T05:44:07Z","sha256":"99cea398da3fc795f72f35d510d12b8fdbaa4311da131f3ff0bd1e11a8081f63","source_id":"us-dc","stale":false,"prev":"us-dc/d.c.-code-7-1671.01-perm","next":"us-dc/d.c.-code-38-504-perm"},"notice":"GroundRules: Original legal text. Not legal advice."}